GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Cyclically Adjusted FCF per Share

Pharmicell Co (XKRX:005690) Cyclically Adjusted FCF per Share : ₩-59.99 (As of Mar. 2025)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pharmicell Co's adjusted free cash flow per share for the three months ended in Mar. 2025 was ₩-18.780. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₩-59.99 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 23.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pharmicell Co was 28.10% per year. The lowest was 4.20% per year. And the median was 25.75% per year.

As of today (2025-07-15), Pharmicell Co's current stock price is ₩13020.00. Pharmicell Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ₩-59.99. Pharmicell Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharmicell Co was 70.08. The lowest was 59.58. And the median was 63.36.


Pharmicell Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Pharmicell Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Cyclically Adjusted FCF per Share Chart

Pharmicell Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -222.39 -131.04 -106.19 -84.13 -57.93

Pharmicell Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.81 -78.53 -64.27 -57.93 -59.99

Competitive Comparison of Pharmicell Co's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Pharmicell Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

Pharmicell Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharmicell Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-18.78/122.5900*122.5900
=-18.780

Current CPI (Mar. 2025) = 122.5900.

Pharmicell Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -45.992 100.051 -56.353
201509 -106.728 100.111 -130.693
201512 -17.555 100.220 -21.473
201603 3.051 100.561 3.719
201606 -6.401 100.791 -7.785
201609 -19.426 101.461 -23.471
201612 -26.789 101.561 -32.336
201703 -13.636 102.851 -16.253
201706 0.303 102.611 0.362
201709 -59.792 103.491 -70.827
201712 -36.353 102.991 -43.271
201803 -38.719 104.101 -45.596
201806 -9.948 104.130 -11.712
201809 -12.359 105.651 -14.341
201812 42.833 104.351 50.320
201903 -24.582 104.491 -28.840
201906 2.184 104.881 2.553
201909 -20.739 105.200 -24.167
201912 10.351 105.121 12.071
202003 32.583 105.354 37.914
202006 56.162 105.112 65.501
202009 49.020 106.198 56.587
202012 -0.880 105.765 -1.020
202103 -26.349 107.357 -30.088
202106 26.199 107.579 29.855
202109 48.352 108.759 54.501
202112 -206.995 109.676 -231.367
202203 29.732 111.848 32.587
202206 -78.006 114.072 -83.831
202209 -127.698 114.715 -136.464
202212 -6.186 115.179 -6.584
202303 41.629 116.507 43.802
202306 66.585 117.182 69.658
202309 10.743 118.964 11.070
202312 -18.959 118.837 -19.558
202403 -59.099 120.123 -60.313
202406 -44.270 120.007 -45.223
202409 90.352 120.861 91.644
202412 -1.646 121.135 -1.666
202503 -18.780 122.590 -18.780

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Pharmicell Co  (XKRX:005690) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharmicell Co was 70.08. The lowest was 59.58. And the median was 63.36.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pharmicell Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines